Skip to main content
Novartis
language-selector-globe United States | en
Choose Location
  • Americas
  • Asia Pacific
  • Europe
  • International
  • Middle East & Africa
Argentina | Español
Brazil | Português
Canada | English
Canada | Français
Central America | Español
Colombia | Español
Mexico | Español
United States | English
Australia | English
Bangladesh | English
Hong Kong S.A.R. | 繁體中文
India | English
Indonesia | English
Japan | 日本語
Korea | 한국어
Mainland China | 中文
Malaysia | English
Pakistan | English
Philippines | English
Singapore | English
Taiwan | 繁體中文
Thailand | ภาษาไทย
Austria | Deutsch
Belgium | Français
Belgium | Nederlands
Bulgaria | Български
Czech Republic | Česky
Czech Republic | English
Denmark | Dansk
Estonia | Eesti
Finland | Suomalainen
France | Français
Germany | Deutsch
Greece | Ελληνικά
Hungary | Magyar
Ireland | English
Italy | Italiano
Latvia | Latvian
Lithuania | Lithuanian
Netherlands | Nederlands
Norway | Norsk
Poland | Polski
Portugal | Português
Romania | Română
Russia | Русский
Serbia | Srpski
Slovakia | Slovensky
Slovenia | Slovenščina
Slovenia | English
Spain | Español
Sweden | Svenska
Switzerland | Deutsch
Switzerland | Français
Türkiye | Türkçe
United Kingdom | English
Global | English
Novartis Foundation | English
Egypt | English
Israel | עברית
Saudi Arabia | العربية
South Africa | English
language-selector-globe us
Choose Location
Americas Asia Pacific Europe International Middle East & Africa
Argentina | Español
Australia | English
Austria | Deutsch
Bangladesh | English
Belgium | Français
Belgium | Nederlands
Brazil | Português
Bulgaria | Български
Canada | English
Canada | Français
Central America | Español
Colombia | Español
Czech Republic | Česky
Czech Republic | English
Denmark | Dansk
Egypt | English
Estonia | Eesti
Finland | Suomalainen
France | Français
Germany | Deutsch
Greece | Ελληνικά
Hong Kong S.A.R. | 繁體中文
Hungary | Magyar
India | English
Indonesia | English
Ireland | English
Israel | עברית
Italy | Italiano
Japan | 日本語
Korea | 한국어
Latvia | Latvian
Lithuania | Lithuanian
Mainland China | 中文
Malaysia | English
Mexico | Español
Netherlands | Nederlands
Norway | Norsk
Global | English
Novartis Foundation | English
Pakistan | English
Philippines | English
Poland | Polski
Portugal | Português
Romania | Română
Russia | Русский
Saudi Arabia | العربية
Serbia | Srpski
Singapore | English
Slovakia | Slovensky
Slovenia | Slovenščina
Slovenia | English
South Africa | English
Spain | Español
Sweden | Svenska
Switzerland | Deutsch
Switzerland | Français
Taiwan | 繁體中文
Thailand | ภาษาไทย
Türkiye | Türkçe
United Kingdom | English
United States | English
    • About 
      • Novartis in the US 
        • Diversity equity & inclusion  
        • Pay transparency-EPIC 
        • Our code of ethics 
      • Diversity, equity & inclusion  
        • Novartis US EEO / D&I report 2021 
        • Supplier diversity 
      • People and culture 
      • Products 
      • US Country Coordinating Committee 
      • External funding 
      • Contact us 
      Team meeting
      About
    • Patients and caregivers 
      • Novartis commitment to patients and caregivers 
      • Patient assistance 
      • Diseases 
        • Chronic spontaneous urticaria (CSU) 
        • Hidradenitis suppurativa (HS) 
        • Prostate Cancer (PC) 
        • Paroxysmal Nocturnal Hemoglobinuria (PNH) 
      • Participating in clinical trials 
      • Patient perspectives 
      • Adverse event reporting 
      • The STEP program 
        • Sickle cell disease (SCD) 
        • Program overview 
        • Multiple sclerosis (MS) 
        • Cancer 
        • Application for funding to help address health disparities 
        • Health disparities 
      • Patient resources 
      Patient smiling at doctor image
      Patients and caregivers
    • Healthcare professionals 
      • Novartis pipeline 
      • Novartis clinical trials 
      • Adverse event reporting 
      • HCP resources 
      • Personalized and Precision Medicine 
      • Health Information Technology Resources 
      Two doctors examining X-ray
      Healthcare professionals
    • ESG 
      • Ethical behavior 
        • Code of ethics 
        • SpeakUp 
        • PhRMA Code on interactions with healthcare professionals 
        • Business principles 
      • Ethics, risk and compliance 
        • Compliance program 
        • State laws 
        • Corporate integrity agreement 
        • Payments to HCPs & HCOs 
        • Drug Supply Chain Security Act Information 
      • Corporate responsibility 
        • Population health 
        • Novartis in society US reports 
        • Novartis US Foundation 
        • Environmental sustainability 
        • People and communities 
      • Beacon of hope 
        • Beacon of hope: Measurable solutions for health equity 
        • Paving the way for a brighter, more equitable future 
      Novartis East Hanover Campus Landscaping
      ESG
    • News 
      • News archive 
      • Statements 
      • Stories 
      • Contacts 
      Co-workers having a meeting
      News
    • Careers 
      • Career search 
      • Meet the teams 
      • Early career 
      • Personal growth 
      • How we work 
      • Employee benefits 
      • Diversity, equity & inclusion 
      • Awards & recognition 
      Meeting in Atrium
      Careers
    Grandmother, mother and daughter smiling and laughing on a beach
    Home
Medical Innovations

Medical Innovations

Tags Archive Navigation
  • All
  • Careers
  • Feature News
  • In the News
  • Media Releases
  • Story
icon
  • Media Release
    Mar 17, 2023
    Novartis Tafinlar + Mekinist approved by FDA for pediatric patients with BRAF V600E low-grade glioma, the most common pediatric brain cancer

Pagination

Novartis United States

Navigate Novartis
  • Patients & caregivers
  • Healthcare professionals
  • ESG
  • News
  • Careers
Media center
  • News archive
  • Statements
  • Stories
Our portfolio
  • Novartis clinical pipeline
  • Novartis product portfolio
Other Novartis US websites
  • Oncology HCP resources
  • Medical information
  • Global site
Footer Bottom
© 2024 Novartis Pharmaceuticals Corporation
  • Terms of use
  • Privacy policy
  • Consumer health privacy policy
  • Contacts
  • Site map
  • Web accessibility
Novartis Site Directory
This site is intended for US residents only